ADx NeuroSciences, a wholly owned subsidiary of Fujirebio, and immunoassay developer Alamar Biosciences will collaborate on the development of customized biomarker assays for pharmaceutical companies devising therapeutics for neurodegenerative diseases.
The partnership will use Alamar's Nulisa (nucleic acid-linked immuno-sandwich assay) immunoassay platform and the Argo HT System to develop assays for the detection and quantification of critical biomarkers for neurodegenerative diseases, including Alzheimer's disease, Parkinson's, and amyotrophic lateral sclerosis, the firms said in a statement.
"By adding the NULISA platform with its remarkable sensitivity to our range of possible platforms, it enforces our capabilities to support our pharma network in their search for tailor-made biomarkers," Koen Dewaele, CEO of the Ghent, Belgium-based ADx NeuroSciences, said.
Financial and other terms of the agreement have not been disclosed.
